Predictive Oncology Sends Letter to Shareholders Regarding Special Meeting to be Reconvened on December 30, 2020
December 09 2020 - 08:30AM
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company
focused on applying artificial intelligence (“AI”) to personalized
medicine and drug discovery, today sent a letter to shareholders
regarding its virtual Special Meeting of Stockholders, original
scheduled for December 1, 2020, which will be reconvened December
30, 2020 at 3 p.m. CST.
The Board of Directors and management of
Predictive Oncology urge all shareholders to vote “FOR” the
proposals being considered at the Special Meeting, primarily
because the reincorporation in Nevada will
eliminate our obligation to pay the injurious annual
Delaware franchise tax, which is currently equal
to approximately $170,000 per year. The
company can save approximately $158,000 annually
in state taxes by reincorporating in Nevada.
The full text of the letter follows:
December 9, 2020
Dear Shareholder,
Our Special Meeting of the Shareholders on
December 1, 2020 was adjourned to December 30, 2020. We need your
vote!
We previously sent you proxy materials in
connection with our Special Meeting of Shareholders, and according
to our records, we have not yet received your vote.
We are asking you to vote for allowing the
Company to reincorporate in the state of Nevada, moving away from
Delaware. Our Board believes that there are several reasons why a
reincorporation in Nevada is in the best interests of the Company
and our stockholders. First and foremost, the
reincorporation in Nevada will eliminate our
obligation to pay the injurious annual Delaware franchise
tax, which is currently equal to approximately
$170,000 per year. We can save approximately
$158,000 annually in state taxes by reincorporating in
Nevada. Also, we believe that for the reasons
described in the proxy materials, in general, Nevada law provides
greater protection to our directors, officers and the Company than
Delaware law.
Your vote is very important,
regardless of the number of shares you own.
The reincorporation, to be approved at the
Special Meeting, must receive a “For” vote from a
majority of the outstanding shares of common stock of the Company.
At our recent Annual Meeting, the Reincorporation vote received far
more “For” votes than “Against” votes, however, we did not reach
the required number of total votes for a majority of the
outstanding shares.
Please take a moment to vote your shares by
following the instructions in your proxy materials. You may vote
online or by telephone.
Please disregard this letter if you have already
voted your shares for the reincorporation.If you have any concerns
please contact either Bob Myers or me.
Carl Schwartz – cisdds13@gmail.comBob Myers –
bmyers@skylinemedical.com
Thank you for your cooperation and support.
Sincerely,
Carl SchwartzChief Executive Officer
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release
contain forward-looking statements. These forward-looking
statements reflect our current expectations and projections about
future events and are subject to substantial risks, uncertainties
and assumptions about our operations and the investments we make.
All statements, other than statements of historical facts, included
in this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, factors discussed under the heading
“Risk Factors” in our filings with the SEC. Except as expressly
required by law, the Company disclaims any intent or obligation to
update these forward-looking statements.
Investor Relations Contact:
Hayden IRJames Carbonara(646)-755-7412
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2023 to Mar 2024